Which Health Screening Tests Actually Matter? A Doctor's Guide

Screening looks for disease or risk factors before symptoms appear. Once symptoms are present, the task changes from screening to diagnostic evaluation. That distinction matters because the appropriate test, urgency and interpretation can be very different.

Healthier SG recommends cardiovascular risk screening for eligible adults aged 40 and above who do not already have hypertension, diabetes or high cholesterol, generally at three-year intervals. Younger adults may need earlier assessment when risk is elevated.

Two points specific to Singapore are worth knowing. Asian populations develop diabetes risk at a lower BMI than European populations, with correspondingly lower waist thresholds — so appearing slim does not exclude meaningful metabolic risk. And under Healthier SG, enrolled residents can access subsidised nationally recommended screening, which makes paying privately for those same tests an unnecessary expense for many people.

Breast, cervical and colorectal cancer screening have established population-based roles in Singapore. Lung cancer screening is targeted to selected high-risk individuals rather than the general population. Other tests may be appropriate because of symptoms, family history or a specific clinical indication.

The three population programmes share something worth noting: they exist because trials showed they reduce deaths from those cancers. That is a higher bar than a test simply being able to detect something, and it is the reason these are recommended while many other cancer tests are not.

A screening test can detect an abnormality that is harmless, transient or unrelated to future illness. This can lead to repeat blood tests, scans, biopsies, anxiety and cost.

The arithmetic people are not shown

Consider a test that is 99% specific, applied to a condition affecting one person in a thousand. Screen 10,000 healthy people and roughly 100 will be told they have an abnormal result, while about 10 actually have the condition. The great majority of alarms are false — not because the test is poor, but because the condition is uncommon in the people being tested.

Now apply that to a package containing thirty separate tests. The chance that at least one comes back marginally outside the reference range approaches certainty, and each of those results generates a repeat test, a scan or a specialist referral.

Whole-body imaging and broad panels also need careful interpretation. The right question is not “how many tests are included?” but “which results would change management for this person?”

Overdiagnosis is the subtler harm. Some detected abnormalities would never have caused symptoms in a person's lifetime, but once found they are usually treated — with all the cost, risk and anxiety treatment carries, and no benefit, because there was nothing to prevent.

Packages are typically priced and marketed by the number of tests included, which is precisely the wrong metric. A useful package is one where each test has a reason to be there for you specifically.

• Is a doctor consultation included? A report without interpretation transfers the hardest part to you.
• What happens with an abnormal result? Is follow-up included or charged separately?
• Are nationally recommended screenings included? If not, the package is supplementing rather than covering the basics.
• Does it contain tumour markers for healthy adults? Their presence signals a package built on volume rather than evidence.
• Would you act on the result? A test whose outcome would change nothing is worth skipping.
• Are you eligible for subsidised screening instead? Worth checking before paying privately for the same tests.

Marginally abnormal results are common and frequently not significant. Reference ranges are constructed so that a proportion of healthy people fall outside them by definition, and single values fluctuate with hydration, recent meals, exercise, illness and time of day.

The useful response is rarely alarm or dismissal. It is context: is this a trend or a one-off, does it fit the clinical picture, and would repeating it in a few weeks be more informative than acting now? This is precisely what a results consultation is for, and why a laboratory report emailed without interpretation is worth less than it appears.

Private screening can be useful for convenience, personalised risk assessment, additional tests when justified and coordinated follow-up. It should complement — not compete with — national screening programmes.

At Aquila, screening can be linked with doctor-led health screening, chronic disease follow-up and, when appropriate, a separate biological-age and longevity assessment. These are different goals: standard screening looks for established disease and conventional risk; longevity panels explore broader biomarkers whose clinical utility varies.

Related reading: our guides to multi-cancer early detection, cholesterol management and women's hormone screening cover specific areas in more detail.

• Bring previous results so trends can be compared.
• List all medicines and supplements.
• Know your family history, especially premature cardiovascular disease and cancer.
• Ask whether fasting is genuinely required for the tests being ordered.
• Do not stop prescribed medication unless specifically instructed.
• Plan a results review rather than treating the laboratory report as the end of the process.

Bringing old results is the most undervalued item on that list. A cholesterol figure in isolation says far less than the same figure alongside three previous years, and trends frequently change the decision where a single value would not.